From Inflammation to Thrombosis: The Prothrombotic State and Cardiovascular Risk in Inflammatory Bowel Disease

TL;DR

Inflammatory bowel disease increases blood clot risk through inflammation and immune responses, requiring integrated care to manage cardiovascular risks.

Contribution

The paper highlights a thromboinflammatory phenotype linking intestinal inflammation to systemic vascular effects in IBD.

Findings

IBD is associated with increased venous and moderate arterial cardiovascular risks.

Inflammatory activity and acute care influence thrombotic risk through immune and coagulation pathways.

Personalized risk assessment and mechanism-informed strategies are needed for better management.

Abstract

Inflammatory bowel disease (IBD) is associated with an increased risk of venous thromboembolic events (VTEs) and a moderate risk of arterial cardiovascular events. This varies with inflammatory activity and acute-care exposure, with pathophysiological data supporting a thromboinflammatory phenotype in which intestinal inflammation influences systemic vascular homeostasis through innate immune activation, coagulation–platelet crosstalk, endothelial dysfunction, impaired fibrinolysis, and immunothrombosis. Clinically, prevention and management should be integrated into routine care and anchored in sustained, steroid-sparing disease control, combined with guideline-based in-hospital thromboprophylaxis and standard cardiovascular prevention. Decisions regarding anticoagulant therapy after VTEs should follow established principles while recognizing that recurrence prevention depends not only on anticoagulant choice but also on minimizing repeated inflammatory and treatment-related risk exposures. Cardiovascular risk assessment and optimization of modifiable factors should be considered before therapy escalation or treatment switching. Future advances will likely come from more personalized risk assessment across dynamic high-risk windows and from adjunctive, mechanism-informed strategies targeting key nodes of the gut–vascular interface and immunothrombosis.

Figures